PECULIARITIES OF POLYMORPHISM OF CERTAIN GENES OF THE HEMOSTASIS SYSTEM IN PATIENTS WITH COVID-19

The purpose of the research: to determine the role of polymorphism of a number of genes of the hemostasis system in the course and outcomes of COVID-19.Material and methods. The study included 102 people with extremely severe (Group 1, n = 27), severe (Group 2, n = 53), mild and asymptomatic (Group 3, n = 22) COVID-19. There were 17 patients with a fatal outcome, thrombotic events were noted in 12 people. Allelic variants of genes associated with hemostasis dysfunction (FGB, FII, FV, FVII, F13A1, PAI-I, Gp1a, and Gp3a) were determined using PCR blood samples. Only mutations of high thrombogenic risk FV Leiden and prothrombin (G20210A) were considered thrombophilia. For statistical analysis the Statistic ver. 12 software (Stat Soft, USA) was used. We performed comparative analysis of independent categorical (binary) variables using contingency tables and Pearson's χ2 test with Yates' correction and Fisher's exact test. We calculated risk ratios RRs [CI].Results. Thrombophilia was a predictor of death (RR=3,13 [1,33 - 7,32]), thrombocytopenia RR=13,5 [3,56 - 51,23], and coagulopathy RR=8,4 [2,2 - 21,3] in patients with COVID-19. All patients with fatal COVID-19 (100%) showed the absence of protective polymorphism for FVII 10976 G → A and the carriage of the T risk allele in the alpha-2 integrin gene (Gp1a). COVID-19infection was a significant triggering factor for the phenotypic manifestation of the prothrombogenic genotype with a high relativerisk of thrombotic complications (RR = 22.5 [7.1 - 71.7], sensitivity - 75%, specificity - 97%). Information on the presence of thrombophilia should be used to prescribe therapeutic doses of anticoagulants during hospitalization and to resolve the issue of longterm thromboprophylaxis in the period after COVID-19.

COVID-19, polymorphism, genetics, thrombophilia

1. Host gene variability and SARS-CoV-2 infection: A review article. / I. Kaidashev [et al.] // Heliyon. - 2021. Vol. 7, № 8. - P. e1-10

2. Relevance between COVID-19 and host genetics of immune response. / I. Taher [et al.] // Saudi J Biol Sci. - 2021. - Vol. 28, № 11. - Р.6645-6652

3. Human gene polymorphisms and their possible impact on the clinical outcome of SARS-CoV-2 infection. / S.M.A. Hashemi [et al.] // Archives of Virology. - 2021. - №166. - Р.2089-2108

4. Janssen, R. Vitamin K epoxide reductase complex subunit 1 (VKORC1) gene polymorphism as determinant of differences in COVID19-related disease severity / R. Janssen, J. Walk // Medical Hypotheses. - 2020. -Vol. 144, №110218. - P. e1-3

5. Karst, М. Life-threatening course in coronavirus disease 2019 (COVID-19): is there a link to methylenetetrahydrofolic acid reductase (MTHFR) polymorphism and hyperhomocysteinemia? / M. Karst, J. Hollenhorst, J. Achenbach // Medical Hypotheses. - 2020. -Vol. 144, №110234. - P. e1-3

6. Prognostic Genetic Markers for Thrombosis in COVID-19 Patients: A Focused Analysis on D-Dimer, Homocysteine and Thromboembolism. / M. Abu-Farha [et al.] // Front Pharmacol. - 2020. - Vol. 11, №587451. - P. e1-10

7. Зотова, И.В. Наследственная тромбофилия и венозные тромбоэмболические осложнения: правила тестирования в клинической практике / И.В. Зотова, Д.А. Затейщиков // Российский кардиологический журнал. - 2020. - Т. 25(S3). - С. 55-61

8. Панченко, Д.И. Прогнозирование риска развития фибрилляции предсердий и ишемической болезни сердца при мутации генов системы гемостаза / Д.И. Панченко А.С. Адамчик // Кубанский научный медицинский вестник. - 2018. - Т.25, №5. - С.147-151

9. Клиническая флебология / под ред. Ю.Л. Шевченко, Ю.М. Стойко. - М.: ДПК Пресс, 2016. - 256 с

10. Proposal of the Definition for COVID-19-Associated Coagulopathy. / T. Iba [et al.] // Journal of Clinical Medicine. - 2021. - Vol. 10, № 2. - Р.191

11. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений (ВТЭО) / Л.А. Бокерия [и др.] // Флебология. - 2015. - Т.4, № 2. - С.1-52

12. Medcalf, R.L. Fibrinolysis and COVID-19: A plasmin paradox. / R.L. Medcalf, C.B. Keragala, P.S. Myles // J Thromb Haemost. - 2020. Vol. 18, № 9. - P. 2118-2122

13. Момот, А.П. Проблема тромбофилии в клинической практике / А.П. Момот // Российский журнал детской гематологии и онкологии (РЖДГиО). - 2015. - Т.2, №1. - С.36-48

14. Роль полиморфизмов генов системы гемостаза в патогенезе COVID-19 / В.Н. Городин [и др.] // Инфекционные болезни. - 2021. - Т.19, №2. - С.16-26